Cargando…
The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
The prognosis of diffuse large B‐cell lymphoma (DLBCL) patients depends on lymphoma‐ and patient‐related risk factors and is best estimated by the international prognostic index (IPI). The aim of the study was to determine whether the average relative dose intensity (ARDI) of an anthracycline‐contai...
Autores principales: | Długosz‐Danecka, Monika, Szmit, Sebastian, Ogórka, Tomasz, Skotnicki, Aleksander B., Jurczak, Wojciech |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434223/ https://www.ncbi.nlm.nih.gov/pubmed/30740919 http://dx.doi.org/10.1002/cam4.2008 |
Ejemplares similares
-
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021) -
Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report
por: Drozd-Sokolowska, Joanna, et al.
Publicado: (2020) -
Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers
por: Jurczak, Wojciech, et al.
Publicado: (2015) -
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014) -
Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
por: Kadota, Tomohiro, et al.
Publicado: (2019)